Comparison between 68Ga-bombesin (68Ga-BZH3) and the cRGD tetramer 68Ga-RGD4 studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell line

EJNMMI Research

Volumn 1, Issue 1, 2011, Pages 1-11

  Cheng, Caixia ^a   Pan, Leyun ^a   Dimitrakopoulou Strauss, Antonia ^a   Schäfer, Martin ^a   Wängler, Carmen ^b   Wängler, Björn ^b   Haberkorn, Uwe ^a   Strauss, Ludwig G ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Kinetic modeling; Neuroendocrine tumors; PET

Indexed keywords

GALLIUM ARGINYLGLYCYLASPARTIC ACID 4 GA 68; GALLIUM BOMBESIN GA 68; RADIOPHARMACEUTICAL AGENT; TETRAMER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG STRUCTURE; GENE EXPRESSION REGULATION; IC 50; IMAGE RECONSTRUCTION; IN VIVO STUDY; METASTASIS; NONHUMAN; NUDE RAT; PANCREATIC NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIOISOTOPE DIAGNOSIS; RAT; SCINTIGRAPHY; SUPPORT VECTOR MACHINE; TUMOR CELL LINE;

EID: 84875912176     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-1-34     Document Type: Article

References (50)

1. Hoffman TJ, Quinn TP, Volkert WA: Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells. Nul Med Biol 2001, 28:527-539.
2. Strauss LG, Conti PS: The application of PET in clinical oncology. J Nucl Med 1991, 32:623-648.
3. Sancho V, Di Florio A, Moody TW, Jensen RT: Bombesin receptor-mediated imaging and cytotoxicity: review and current status. Curr Drug Deliv 2011, 8:79-134.
4. Ambrosini V, Tomassetti P, Franchi R, Fanti S: Imaging of NETs with PET radiopharmaceuticals. Q J Nucl Med Mol Imaging 2010, 54:16-23.
5. Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dierckx RA, Paganelli G: Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest 32(4):360-369.
6. Van de Wiele C, Dumont F, Van den Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, Peers S, Thornback J, Slegers G, Dierckx RA: Technetium-99 m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 2000, 27:1694-1699.
7. Breeman WAP, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, Kwekkeboom DJ, Visser TJ, Krenning EP: Preclinical comparison of 111In labeled DTPA-or DOTA-bombesin analogs for receptor targeted scintigraphy and radionuclide therapy. J Nucl Med 2002, 43:1650-1656.
8. Hoffman TJ, Gali H, Smith CJ, Sieckman GL, Hayes DL, Owen NK, Volkert WA: Novel series of In-111 labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 2003, 44:823-831.
9. Van de Wiele C, Dumont F, Dierckx RA, Peers SH, Thornback JR, Slegers G, Thierens H: Biodistribution and dosimetry of 99mTc-RP 527, a gastrinreleasing peptide (GRP) agonist for the visualization of GRP receptorexpressing malignancies. J Nucl Med 2001, 42:1722-1727.
10. Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Kannan R, Volkert WA, Hoffman TJ: Radiochemical investigations of gastrin-releasing peptide receptor-specific [99mTc(X)(CO)3-Dipr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr = 2,3-diaminopropionic acid and × = H2O or P(CH2OH)3. Cancer Res 2003, 63:4082-4088.
11. Nock B, Nikolopoulou A, Chiotellis E, Loudos G, Maintas D, Reubi JC, Maina T: 99mTc-Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumor imaging. Eur J Nucl Med 2003, 30:247-258.
12. Scopinaro F, DeVincentis G, Varvarigou AD, Laurenti C, Iori F, Remediani S, Chiarini S, Stella S: 99mTc-Bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med 2003, 30:1378-1382.
13. Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Volkert WA, Hoffman TJ: Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14) NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies. Anticancer Res 2003, 23:63-70.
14. Dimitrakopoulou-Strauss A, Seiz M, Tuettenberg J, Schmieder K, Eisenhut M, Haberkorn U, Strauss LG: Pharmacokinetic studies of 68Galabeled bombesin (68Ga-BZH3) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading. Clin Nucl Med 2011, 36:101-108.
15. Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Mäcke HR, Eisenhut M, Strauss LG: 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG. J Nucl Med 2007, 48:1245-1250.
16. Singh P, Draviam E, Guo YS, Kurosky A: Molecular characterization of bombesin receptors on rat pancreatic acinar AR42J cells. Am J Physiol 1990, 258:G803-9.
17. vanderSpek JC, Sutherland JA, Zeng H, Battey JF, Jensen RT, Murphy JR: Inhibition of protein synthesis in small cell lung cancer cells induced by the diphtheria toxin-related fusion protein DAB389 GRP. Cancer Res 1997, 57:290-294.
18. Beer AJ, Schwaiger M: Imaging of integrin ανβ3 expression. Cancer Metastasis Rev 2008, 27:631-644.
19. Cai W, Chen X: Anti-angiogenic cancer therapy based on integrinαVβ3 antagonism. Anti Canc Agents Med Chem 2006, 6:407-428.
20. Wellings DA, Atherton E: Standard Fmoc protocols. Methods Enzymol 1997, 289:44-67.
21. Wängler C, Maschauer S, Prante O, Schafer M, Schirrmacher R, Bartenstein P, Eisenhut M, Wängler B: Multimerization of cRGD peptides by click chemistry: synthetic strategies, chemical limitations, and influence on biological properties. Chembiochem 2010, 11:2168-2181.
22. Schuhmacher J, Zhang H, Doll J, Mäcke HR, Matys R, Hauser H, Henze M, Haberkorn U, Eisenhut M: GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin (6-14) analog. J Nucl Med 2005, 46:691-699.
23. Jeong JM, Hong MK, Chang YS, Lee YS, Kim YJ, Cheon GJ, Lee DS, Chung JK, Lee MC: Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 2008, 49:830-836.
24. Pan L, Mikolajczyk K, Strauss LG, Haberkorn U, Dimitrakopoulou-Strauss A: Machine learning based parameter imaging and kinetic modelling of PET data. J Nucl Med 2007, 48(2):158.
25. Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C: A JAVA environment for medical image data analysis: initial application for brain PET quantitation. Med Inform 1998, 23:207-214.
26. Burger C, Buck A: Requirements and implementations of a flexible kinetic modelling tool. J Nucl Med 1997, 38:181-1823.
27. Miyazawa H, Osmont A, Petit-Taboue MC, Tillet I, Travère JM, Young AR, Barré L, MacKenzie ET, Baron JC: Determination of 18F-fluoro-2-deoxy-dglucose rate constants in the anesthetized baboon brain with dynamic positron tomography. J Neurosci Methods 1993, 50:263-272.
28. Sokoloff L, Smith CB: Basic principles underlying radioisotopic methods for assay of biochemical processes in vivo. In The Metabolism of the Human Brain Studies with Positron Emission Tomography. Edited by: Greitz T, Ingvar DH, Widén L. New York, NY: Raven Press; 1983:123-148.
29. Strauss LG, Pan L, Koczan D, Klippel S, Mikolajczyk K, Burger C, Haberkorn U, Schönleben K, Thiesen HJ, Dimitrakopoulou-Strauss A: Fusion of positron emission tomography (PET) and gene array data: a new approach for the correlative analysis of molecular biological and clinical data. IEEE Trans Med Imaging 2007, 26:804-812.
30. Dimitrakopoulou-Strauss A, Strauss LG, Mikolajczyk Burger C, Lehnert T, Bernd L, Ewerbeck V: On the fractal nature of dynamic positron emission tomography (PET) studies. World J Nucl Med 2003, 2:306-313.
31. Guyon I, Weston J, Barnhill S, Vapnik V: Gene selection for cancer classification using support vector machines. Mach Learn 2002, 46:389-422.
32. Hawkins RA, Choi Y, Hung S, Messa C, Hoh CK, Phelps ME: Quantitating Tumor Glucose Metabolism with FDG and PET. J Nucl Med 1992, 33:339-344.
33. Kaltsas G, Besser M, Grossman A: The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004, 25:458-511.
34. Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G: Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998, 25:79-83.
35. Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, Hennig M: Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumor-targeting properties and potential for receptor-medicated internal radiotherapy. Chem Eur J 1999, 5:1974-1981.
36. Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, Dimitrakopoulou-Strauss A: Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006, 33:460-466.
37. Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A: Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006, 33:1115-1122.
38. Sharif TR, Luo W, Sharif M: Functional expression of bombesin receptor in most adult and pediatric human glioblastoma cell lines; role in mitogenesis and in stimulating the mitogen-activated protein kinase pathway. Mol Cell Endocrinol 1997, 130:119-130.
39. Jensen RT, Battey JF, Spindle ER, Benya RV: International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signalling, and functions in normal and disease states. Pharmacol Rev 2008, 60:1-42.
40. Ait-Mohand S, Fournier P, Dumulon-Perreault V, Kiefer GE, Jurek P, Ferreira CL, Benard F, Guerin B: Evalution of 64Cu-labeled bifunctional chelate-bombesin conjugates. Bioconjug Chem 2011, 22:1729-1735.
41. Santos-Cuevas CL, Ferro-Flores G, Rojas-Calderon EL, Garcia-Becerra R, Ordaz-Rosado D, Arteaga de Murphy C, Pedraza-Lopez M: 99mTc-N2S2-Tat (49-57)-bombesin internalized in nuclei of prostate and breast caner cells: kinetics, dosimetry and effect on cellular proliferation. Nucl Med Commun 2011, 32:303-313.
42. Hood JD, Cheresh DA: Role of integrins in cell invasion and migration. Nature Reviews Cancer 2002, 2:91-100.
43. Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, Arnaout MA: Crystal structure of the extracellular segment of integrin ανβ3 in complex with an Arg-Gly-Asp ligand. Science 2002, 296:151-155.
44. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, Stöcklin G, Schwaiger M: Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999, 40:1061-1071.
45. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M: Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001, 61:1781-1785.
46. Haubner R: αvβ3-Integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 2006, 33:54-63.
47. Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dierckx RA, Paganelli G: Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest 2009, 32:360-369.
48. Dimitrakopoulou-Strauss A, Strauss LG, Burger C: Quantitative PET studies in pretreated melanoma patients: a comparison of 6-(18F)-fluoro-L-dopa with 18F-FDG and 15O-water using compartment and noncompartment analysis. J Nucl Med 2001, 42:248-256.
49. Baish JW, Jain RK: Fractals and cancer. Cancer Res 2001, 61:8347-8350.
50. Dimitrakopoulou-Strauss A, Georgoulias V, Eisenhut M, Herth F, Koukouraki S, Mäcke HR, Haberkorn U, Strauss LG: Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using 68Ga-DOTATOC PET and comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2006, 33:823-830.